Pilot Study: Establishing Glutamatergic Changes in Rapid Antidepressant Effects of Ketamine
This open-label, early Phase I trial (n=10) will investigate the effects of a single intravenous ketamine infusion (0.5 mg/kg over 40 minutes) on glutamatergic activity and synaptic strength in individuals with treatment-resistant major depressive disorder (MDD).
Details
This single-group, early-phase study will use GluCEST imaging at 7T to measure glutamatergic activity and inferred synaptic strength before and after a single intravenous ketamine infusion (0.5 mg/kg, 40 minutes) in people with treatment-resistant MDD.
Participants complete baseline clinical assessments (SCID, HAM-D, PANAS, VAS, POMS), a baseline MRI, the ketamine infusion with continuous vital monitoring, post-infusion mood assessments, a one-hour observation period, and a follow-up MRI later the same day to assess acute changes in glutamatergic signal.